patent portfolio overview
- Single mutant toxin patents
- Combination vaccine patent
- RNA vaccine
- Hyperimmune serum patent
- Synthetic antibodies to toxins
Our findings lead to the conclusion that a platform to fight toxins of multiple gram-positive and gram-negative bacteria can be further developed and rolled out. It is not harming any patents of third parties, and it has the full freedom to operate.